Alphyn Biologics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Alphyn Biologics, Inc. - overview
Established
2019
Location
Annapolis, MD, US
Primary Industry
Biotechnology
About
Based in Maryland, US, and founded in 2019 by Neal Koller (CEO), Alphyn Biologics, Inc. Fka Alphyn Biologics, LLC, operates as a dermatology company that improves people's lives by curing the most difficult, severe skin diseases. In December 2025, Alphyn Biologics raised 25 million in series B funding led by Queen City Angels, with participation from Angel Physicians Fund and Serial Stage Venture Partners. Alphyn Biologics created a product called AB-101's that offers numerous benefits such as pre-clinical testing requirements, animal testing requirements, moving directly to Phase 2 human clinical trials, and so on.
The AB-101 platform biomaterial will be used to target the most difficult, severe, and prevalent skin diseases confronting humanity. Furthermore, atopic dermatitis is AB-101's first target disease (or AD, also known as Eczema). The company generates revenue through licensing, partnerships, and milestone payments for dermatology therapeutics. The company plans to use the December 2025 funding to support its global Phase 2b trial for atopic dermatitis, start a Phase 2 programme for molluscum contagiosum, and expand raw material supply.
Current Investors
Queen City Angels, Stage Venture Partners, Angel Physicians Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Dermatology
Website
www.alphynbiologics.com/
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Alphyn Biologics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.